Novavax COVID-19 vaccine gets emergency use approval in PH
MANILA, Philippines — The Food and Drug Administration of the Philippines on Wednesday granted emergency use authorization for Covovax, the COVID-19 vaccine developed by U.S.-based biotechnology firm Novavax.
This is the ninth vaccine against COVID-19 that was granted an EUA in the Philippines, making it available for use.
FDA Director-General Eric Domingo on Wednesday said the vaccine is administered in two doses with a three- to four-week interval. It was approved for use on adults 18 and above.
It has an efficacy rate of 89.7% and has reported “very mild adverse events.”
“Maganda ang safety profile [ng vaccine],” Domingo said in a Laging Handa public briefing.
(It’s safety profile is good.)
Domingo said Covovax is a protein-based vaccine, which is a conventional approach that uses purified pieces of the virus to spur an immune response.
Subscribe to our daily newsletter
The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.
Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.